Interestingly, several interventions targeting CD33 are also tested as potential therapies for Alzheimer’s disease (AD), as reduced cell surface CD33 levels allowed more efficient phagocytic clearance of pathogenic Amyloid beta (Aβ) and provide protection against disease. Here, CD33 is linked to early-onset autosomal dominant Alzheimer disease.